Erasca Inc. (ERAS)
NASDAQ: ERAS · Pharmaceutical Preparations · San Diego, CA
Our rating: Neutral
Call changed from Cautious to Neutral at $15.66, low conviction, November 13, 2026.
Breaks if: The Neutral call turns Cautious if the stock falls more than 35% from today's $15.66 within roughly six months — a decline of that magnitude would almost certainly reflect a clinical setback or financing stress not yet captured in the figures — or if the next 10-Q discloses a cash balance below $400 million, implying fewer than five quarters of runway at the current burn rate. It turns Positive if Erasca reports a statistically significant positive pivotal readout or receives FDA acceptance of a New Drug Application for a lead candidate before the end of the second quarter of 2027.
Key figures
| Market value | $4.8B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | −$308M |
| Free cash flow, last 12 months | −$109M |
| Price to earnings | n/a |
| Free cash flow yield | −2.3% |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −48.7% |
| Beta to the S&P 500 | 1.43 |
| Volatility, annualized | 90.3% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | n/a | n/a | $-0.15 | −$33M |
| June 30, 2026 | n/a | n/a | $-0.14 | −$27M |
| March 31, 2026 | n/a | n/a | $-0.60 | −$27M |
| December 31, 2025 | n/a | n/a | $-0.10 | −$22M |
| September 30, 2025 | n/a | n/a | $-0.11 | −$22M |
| June 30, 2025 | n/a | n/a | $-0.12 | −$21M |
| March 31, 2025 | n/a | n/a | $-0.11 | −$32M |
| December 31, 2024 | n/a | n/a | $-0.09 | −$25M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 3%, Gemini 3%, Mistral 2%
- Free cash flow for the quarter is above zero: Claude 4%, Gemini 3%, Mistral 2%
37 ledger entries and 9 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.